Plan

Nu Ride Inc., Formerly Known as Lordstown Motors Corp., Emerges from Chapter 11 with the New Ticker Symbol "NRDE" on the OTC Pink Market

Retrieved on: 
Thursday, March 14, 2024
United States bankruptcy court, Bankruptcy, Plan

NEW YORK, March 14, 2024 /PRNewswire/ -- Nu Ride Inc., formerly known as Lordstown Motors Corp ("Nu Ride" or the "Company") announced today that it has successfully emerged from bankruptcy pursuant to its confirmed plan of reorganization (the "Plan").

Key Points: 
  • NEW YORK, March 14, 2024 /PRNewswire/ -- Nu Ride Inc., formerly known as Lordstown Motors Corp ("Nu Ride" or the "Company") announced today that it has successfully emerged from bankruptcy pursuant to its confirmed plan of reorganization (the "Plan").
  • The Plan was confirmed by the United States Bankruptcy Court for the District of Delaware (the "Bankruptcy Court") on March 6, 2024.
  • Upon emergence the Company's common stock was issued a new ticker symbol: "NRDE" on the OTC Pink Market.
  • Additional information about the Company and the Plan is available on the company's website ( www.nurideinc.com ) and in the Company's filings with the U.S. Securities and Exchange Commission, available at www.sec.gov/edgar .

OPTRUST FULLY FUNDED FOR 15TH CONSECUTIVE YEAR

Retrieved on: 
Tuesday, March 12, 2024
MDI, Retirement, Risk, Pension, Climate change, Plan, OPTrust, Pension fund

In 2023, OPTrust remained fully funded for the 15th consecutive year and achieved a net investment return of 5.3 per cent.

Key Points: 
  • In 2023, OPTrust remained fully funded for the 15th consecutive year and achieved a net investment return of 5.3 per cent.
  • "At OPTrust, we have a clear purpose – to deliver peace of mind in retirement to our members," said Peter Lindley, President and CEO of OPTrust.
  • "For the 15th consecutive year, OPTrust is fully funded, and the people we serve can continue to rely on a secure, sustainable pension."
  • In 2023, OPTrust welcomed five additional nonprofit organizations and nearly 1,000 new members to reach a total membership of over 4,200 in OPTrust Select.

NEW YORK COMMUNITY BANCORP, INC. CLOSES OVER $1 BILLION EQUITY INVESTMENT STRENGTHENING BALANCE SHEET AND LIQUIDITY POSITION

Retrieved on: 
Tuesday, March 12, 2024
Transfer, Slate, Exercise, Bank Holding Company Act, Sullivan & Cromwell, New York Community Bank, NYCB, Investment, Latham & Watkins, Treasury, Employment, COI, Certificate, Oliver Cromwell, Workforce, Common stock, New York Stock Exchange, Plan, Regulation, Acquisition, Incoming, Growth, Comptroller, Venture round, Jefferies Group, Security (finance)

HICKSVILLE, N.Y., March 11, 2024 /PRNewswire/ -- New York Community Bancorp, Inc. (NYSE: NYCB) ("NYCB" or the "Company") announced today it completed the previously announced transactions resulting in individual investments aggregating to approximately $1.05 billion in the Company by Liberty Strategic Capital ("Liberty"), funds managed by Hudson Bay Capital Management ("Hudson Bay"), funds managed by Reverence Capital Partners ("Reverence Capital"), and other investors (collectively, the "Investors").

Key Points: 
  • Our Company enters this next phase with an enhanced balance sheet and liquidity position."
  • We believe that this transaction has strengthened the Company's balance sheet and liquidity position and look forward to working with management and the dedicated workforce of NYCB to deliver shareholder value."
  • Mr. DiNello, Marshall Lux, Lawrence Savarese, Peter Schoels, David Treadwell and Jennifer Whip remain members of the Board.
  • In addition, in connection with Reg Y Transfers, the Series C Preferred Stock is automatically convertible into 1,000 shares of our common stock.

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 11, 2024
Research, GDF15, PSC, Part, Vomiting, Pregnancy, MSS, Liver, Atlas, Preterm birth, NGM, LAIR1, Nausea, Hospital, ILT3, GFRAL, Food and Drug Administration, NASH, Therapy, Woman, Toxicology, Liver disease, CRC, Cirrhosis, Biomarker, Place of birth, Colorectal cancer, Agreement, Acquisition, Plan, FGF19, AASLD, FDA, Food, Weight loss, Primary sclerosing cholangitis, Pembrolizumab, Dehydration, Bile, Hyperemesis gravidarum, HG, Patient, Pre-eclampsia, Malnutrition, Pharmaceutical industry

--On February 26, 2024, announced that it had entered into the Agreement and Plan of Merger with Atlas Neon Parent, Inc., and Atlas Neon Merger Sub, Inc.--

Key Points: 
  • The combination of NGM707 and pembrolizumab was generally well-tolerated at all four doses (200, 600, 1200, 1800 mg) of NGM707.
  • Additional details can be found in NGM Bio’s recent filings with the United States Securities and Exchange Commission (SEC).
  • NGM Bio anticipates that the Offer and the Merger contemplated under the Merger Agreement will be consummated in the second quarter of 2024.
  • If the Merger is effected, NGM Bio’s common stock will be delisted from The Nasdaq Stock Market LLC and NGM Bio will be privately held.

WaveDancer Encourages Stockholders to Vote FOR the Proposals in Advance of the March 14, 2024 Special Meeting

Retrieved on: 
Monday, March 11, 2024
Ability, Plan, Prospectus, My Little Pony, Register, Person, WAVD, Sale, Transaction, Proxy, FFN, Potential, Holding company

FAIRFAX, Va., March 11, 2024 (GLOBE NEWSWIRE) -- WaveDancer, Inc. (Nasdaq: WAVD) encourages its stockholders to participate actively by casting their vote now for the upcoming meeting of stockholders on March 14, 2024.

Key Points: 
  • FAIRFAX, Va., March 11, 2024 (GLOBE NEWSWIRE) -- WaveDancer, Inc. (Nasdaq: WAVD) encourages its stockholders to participate actively by casting their vote now for the upcoming meeting of stockholders on March 14, 2024.
  • “The Board and I firmly believe that voting FOR each of the proposals is in the best long-term interest of the company’s stockholders,” said Jamie Benoit, CEO of WaveDancer.
  • “But even if you don’t want to vote FOR, what’s most important is that you vote.
  • A special meeting of WaveDancer’s stockholders to approve the merger will be held on March 14, 2024.

Court Grants Final Approval in General Electric ERISA Case

Retrieved on: 
Monday, March 11, 2024
Plan, Vexatious litigation, Retirement, Sale, District court, ERISA, State Street, Defendant, Settlement

BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- Judge Indira Talwani of the United States District Court for the District of Massachusetts has granted final approval of a $61 million cash settlement in IN RE: GE ERISA LITIGATION.

Key Points: 
  • BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- Judge Indira Talwani of the United States District Court for the District of Massachusetts has granted final approval of a $61 million cash settlement in IN RE: GE ERISA LITIGATION.
  • Subsequently, other firms joined and co-litigated the matter on behalf of a nationwide class for almost 8 years through hard fought litigation and settlement.
  • “This is the largest settlement ever in an ERISA case alleging a retirement plan improperly offered proprietary funds.
  • “This was a long and hard-fought case and illustrates that Sanford Heisler Sharp will go the distance and is in these cases for the long haul,” Field said.

KULR Technology Receives Acceptance of Compliance Plan by NYSE American

Retrieved on: 
Friday, March 8, 2024
SAN, Letter, Plan, KULR, Financial adviser

SAN DIEGO, March 08, 2024 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a global leader in sustainable energy management, received notification (the “Acceptance Letter”) from NYSE American LLC (“NYSE American”) that the Company’s previously-submitted plan (the “Plan”) to regain compliance with NYSE American’s listing standards was accepted.

Key Points: 
  • SAN DIEGO, March 08, 2024 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a global leader in sustainable energy management, received notification (the “Acceptance Letter”) from NYSE American LLC (“NYSE American”) that the Company’s previously-submitted plan (the “Plan”) to regain compliance with NYSE American’s listing standards was accepted.
  • In the Acceptance Letter, the NYSE American granted the Company a plan period through June 20, 2025 to regain compliance with the continued listing standards.
  • If the Company does not regain compliance with the NYSE American listing standards by June 20, 2025, or if the Company does not make sufficient progress consistent with the Plan, then the NYSE American may initiate delisting proceedings.
  • The Company’s stock will continue to be listed on the NYSE American during the plan period.

KP Tissue declares a Quarterly Dividend of $0.18 per Common Share

Retrieved on: 
Thursday, March 7, 2024
DRIP, WIRE, Plan, Interest, Income Tax Act, TSX, Dividend, Indian stock exchange, KPT, NOT, Corporation, Partnership, Holding company

MISSISSAUGA, Ontario, March 07, 2024 (GLOBE NEWSWIRE) -- KP Tissue Inc. (“KPT”) (TSX: KPT) announced today that the Board of Directors has declared a quarterly dividend of $0.18 per common share, payable on April 15, 2024, to shareholders of record at the close of business on April 1, 2024, subject to applicable law.

Key Points: 
  • The dividends paid are designated as "eligible" dividends for the purposes of the Income Tax Act (Canada) and any similar provincial and territorial legislation.
  • The dividend is being declared in connection with the declaration of a corresponding quarterly distribution by Kruger Products in which KP Tissue holds a limited partnership interest.
  • The Corporation has a Dividend Reinvestment Plan under which eligible shareholders may elect to have their cash dividends reinvested in additional common shares of KPT.
  • Under the Plan, the Corporation will automatically reinvest for participating shareholders the cash dividends of KPT in newly issued Common Shares at a price per Common Share equal to 100% of the 5-day weighted average trading price of the Common Shares prior to the dividend payment date.

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, March 1, 2024
Cancer, Plan, DSM-IV codes, Patient, Employment

The shares underlying each employee’s stock options will vest 1/16 on a quarterly basis over four years, in each case subject to each such employee’s continued employment with the Company on such vesting dates.

Key Points: 
  • The shares underlying each employee’s stock options will vest 1/16 on a quarterly basis over four years, in each case subject to each such employee’s continued employment with the Company on such vesting dates.
  • All of the above-described awards were made under Biomea’s 2023 Inducement Equity Plan (the “Plan”).
  • The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan.
  • The Plan was adopted by Biomea’s board of directors on November 17, 2023.

Sovos Brands Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Wednesday, February 28, 2024
Plan, Campbell Soup Company, Second request, Growth, IPO, Yoy, Certification, Fiscal, Sub, Pharmaceutical industry

LOUISVILLE, Colo., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sovos Brands, Inc. (“Sovos Brands” or the “Company”) (Nasdaq: SOVO), one of the fastest-growing food companies of scale in the United States, today reported financial results for its fourth quarter and fiscal year ended December 30, 2023.

Key Points: 
  • FY 2023 Net Sales Surpassed $1 Billion; Accelerated Volume Growth Drove
    LOUISVILLE, Colo., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sovos Brands, Inc. (“Sovos Brands” or the “Company”) (Nasdaq: SOVO), one of the fastest-growing food companies of scale in the United States, today reported financial results for its fourth quarter and fiscal year ended December 30, 2023.
  • "Our team delivered sector-leading, volume-driven top and bottom-line growth, surpassing $1 billion of net sales and $150 million of adjusted EBITDA, expanded margins by nearly 200 bps and improved net leverage to 1.6x.
  • Our success would not have been possible without our tenacious and highly talented team and partners who continue to execute with excellence every day."
  • Subject to the satisfaction or waiver of customary closing conditions, the Company continues to expect to complete the Merger within days of the March 11, 2024 expiration date.